Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

NCT00060437 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: perifosine

Sponsor

National Cancer Institute (NCI)